Barr Pharmaceuticals, Inc. is a Delaware holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. The Company’s generic products are marketed under the “Barr” label, and proprietary products are marketed under the “Duramed” label. Barr’s business has two reportable segments: generic pharmaceuticals and proprietary pharmaceuticals. In the generic pharmaceutical segment, the Company currently manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products, representing the largest category of the generic product portfolio. In the proprietary pharmaceutical segment, the Company currently manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the female healthcare arena. These products include the SEASONIQUE™ (levonorgestrel and ethinyl estradiol) extended-cycle oral contraceptive product, ENJUVIA™ (synthetic conjugated estrogens, B) line of hormone therapy products, Plan B® emergency contraceptive (levonorgestrel) product, the ParaGard® T 380A Intrauterine Copper Contraceptive product, and Mircette® oral contraceptive. Barr operates manufacturing, research and development and administrative facilities that are located in eight locations within the United States. Executive offices are located in Woodcliff Lake, New Jersey.